Sign In
Buy SESN
$0.629
+0 (+0%)
At Close: Jun 06, 2023
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
01:13pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
12:51pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disea
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
06:04pm, Monday, 06'th Jun 2022 Zacks Investment Research
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patient
Top Penny Stocks To Buy For Under $1? 3 To Watch This Week
04:41pm, Monday, 06'th Jun 2022 PennyStocks
Stocks Under $1 To Watch This Week.
The post Top Penny Stocks To Buy For Under $1? 3 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Penny Stocks To Buy For Under $1? 3 To Watch This Week
12:41pm, Monday, 06'th Jun 2022
Stocks Under $1 To Watch This Week. The post Top Penny Stocks To Buy For Under $1?
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
07:54pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug
07:26pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
07:20pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
06:25pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
06:22pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
01:00pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start late
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
06:27pm, Tuesday, 31'st May 2022 Zacks Investment Research
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag
02:16pm, Tuesday, 31'st May 2022 Zacks Investment Research
The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.
Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?
02:11pm, Tuesday, 31'st May 2022 Zacks Investment Research
Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.
Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program
02:20pm, Friday, 27'th May 2022 Zacks Investment Research
Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 stu
